XML 64 R14.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
Share-based Compensation Plans
The following table sets forth the detailed allocation of the share-based compensation expense which was included in the Company’s condensed consolidated statements of operations:
 Three Months Ended
(in thousands)March 31, 2023April 1, 2022
Cost of revenue$850 $527 
Research and development expense2,099 2,536 
Selling, general and administrative expense4,475 4,523 
Total$7,424 $7,586 
Restricted Stock Units:
(in thousands, except per share amounts)Number
of
Shares
Weighted Average
Grant-Date Fair Value
Per Share
Balance at December 31, 20223,499 $8.93 
Granted1,216 12.83
Vested(1,500)8.78
Forfeited(229)8.83
Balance at March 31, 20232,986 $10.45 
The Company’s stock benefit plans include the 2002 Employee Stock Purchase Plan (“ESPP”) and current active stock plans adopted in 1995 and 2002 (“1995 Stock Plan” and “2002 Director Plan”, respectively). Refer to Note 13, “Employee Benefit Plans” of Notes to Consolidated Financial Statements in the 2022 Form 10-K for details pertaining to each plan.
As of March 31, 2023, an aggregate of 9,552,296 shares of common stock were reserved for issuance under the 1995 Stock Plan, of which 6,753,467 shares remained available for future grants. As of March 31, 2023, an aggregate of 637,671 shares of common stock were reserved for issuance under the 2002 Director Plan, of which 451,077 shares remained available for future grants.
Share Repurchase Program
In February 2022, the Board of Directors authorized the Company to repurchase up to $100 million of the Company’s outstanding shares of common stock through February 2025. The Company is authorized to repurchase, from time-to-time, shares of its outstanding common stock through open market purchases and 10b5-1 trading plans, in accordance with applicable rules and regulations, at such time and such prices as management may decide. The program does not obligate the Company to repurchase any specific number of shares and may be discontinued at any time. The actual timing and amount of repurchases are subject to business and market conditions, corporate and regulatory requirements, stock price, acquisition opportunities and other factors.
There were no repurchase activities during the three months ended March 31, 2023. As of March 31, 2023, approximately $94.9 million of the share repurchase authorization remained available for repurchases under this program.